NASDAQ:ALLKAllakos Stock Price, Forecast & News

Allakos' stock was trading at $58.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALLK stock has increased by 14.8% and is now trading at $66.90. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allakos.

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Allakos.

Allakos Inc (NASDAQ:ALLK) posted its quarterly earnings results on Monday, May, 11th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.01. View Allakos' earnings history.

3 brokers have issued twelve-month target prices for Allakos' shares. Their forecasts range from $36.00 to $94.00. On average, they anticipate Allakos' stock price to reach $65.00 in the next year. This suggests that the stock has a possible downside of 2.8%. View analysts' price targets for Allakos.

News headlines about ALLK stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Allakos earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View the latest news about Allakos.

Allakos saw a drop in short interest in June. As of June 15th, there was short interest totaling 6,820,000 shares, a drop of 7.3% from the May 31st total of 7,360,000 shares. Based on an average daily volume of 354,600 shares, the days-to-cover ratio is presently 19.2 days. Currently, 27.3% of the shares of the company are sold short. View Allakos' Current Options Chain.

Some companies that are related to Allakos include GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC) and Jazz Pharmaceuticals (JAZZ). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Aimmune Therapeutics (AIMT), Advanced Micro Devices (AMD), Ascendis Pharma A/S (ASND) and Autolus Therapeutics (AUTL).

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALLK stock can currently be purchased for approximately $66.90.

Allakos has a market capitalization of $3.26 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Allakos employs 62 workers across the globe.

The official website for Allakos is www.allakos.com.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]